Laboratorios Richmond SACIF

Laboratorios Richmond SACIF EBIT per Share

The EBIT per Share of Laboratorios Richmond SACIF (RICH.BA) as of Nov 22, 2026 is 192.75 ARS. In the previous year, EBIT per Share was 65.76 ARS — a change of 193.12% (higher).

EBIT per Share

192.75ARS

YoY

193.12%

Last updated:

EBIT per Share of Laboratorios Richmond SACIF is 2024 192.75 ARS. EBIT per Share of Laboratorios Richmond SACIF was 2023 65.76 ARS. It decreases by 193.12% higher compared to the previous year.

The Laboratorios Richmond SACIF EBIT per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT per Share
Date
EBIT per Share
Jan 1, 2017
2.43 ARS
Jan 1, 2018
2.14 ARS
Jan 1, 2019
13.16 ARS
Jan 1, 2020
28.84 ARS
Jan 1, 2021
55.62 ARS
Jan 1, 2022
36.79 ARS
Jan 1, 2023
65.76 ARS
Jan 1, 2024
192.75 ARS
The Laboratorios Richmond SACIF EBIT per Share history
YEAREBIT per ShareYoY
192.75ARS+193.12%
65.76ARS+78.74%
36.79ARS-33.86%
55.62ARS+92.90%
28.84ARS+119.09%
13.16ARS+514.93%
2.14ARS-11.97%
2.43ARS-32.69%
3.61ARS+143.88%
1.48ARS+67.91%
0.88ARS+130.38%
0.38ARS-13.85%
0.44ARS—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Laboratorios Richmond SACIF Stock analysis

What does Laboratorios Richmond SACIF do? Laboratorios Richmond SACIF is a specialized pharmaceutical company focused on the manufacturing and marketing of medications. It was founded in 1935 and is headquartered in Buenos Aires, Argentina. The company has extensive experience in the development of medications and biological products, with expertise in pharmaceutical research and development. It has various business divisions including generics, biological medications, vaccines, oncology medications, and medical devices. The company's products range from simple painkillers and antihistamines to important medications for treating cancer and HIV. Richmond SACIF also manufactures vaccines against diseases such as Hepatitis A and B, polio, influenza, tetanus, and other infectious diseases. Additionally, the company produces a wide range of medications for treating different types of cancer and offers medical instruments and surgical devices. Its business model focuses on innovation and meeting the needs of patients, investing in research and development to develop new and innovative products. The company also has strict quality control measures to ensure the highest pharmaceutical standards. With its rich history and broad range of products, Laboratorios Richmond SACIF is a key player in the global pharmaceutical market and will continue to play an important role in improving the health of people worldwide. Laboratorios Richmond SACIF is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Laboratorios Richmond SACIF stock

EBIT per Share of Laboratorios Richmond SACIF is 192.75 ARS in 2024.

EBIT per Share of Laboratorios Richmond SACIF changed from 65.76 ARS to 192.75 ARS, representing a 193.12% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBIT per Share Laboratorios Richmond SACIF since 2006 – with annual values, charts, and detailed analysis.

EBIT per Share measures operating profit allocated to each outstanding share.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Laboratorios Richmond SACIF

All Key Metrics — Laboratorios Richmond SACIF